FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3155313299> ?p ?o ?g. }

• W3155313299 endingPage "636" @default.
• W3155313299 startingPage "628" @default.
• W3155313299 abstract "This study evaluated cost-effectiveness of defibrotide vs best supportive care (BSC) for the treatment of hepatic veno-occlusive disease/sinusoidal obstructive syndrome (VOD/SOS) with multiorgan dysfunction (MOD) post-hematopoietic cell transplantation (HCT) in Spain.A two-phase Markov model, comprising a 1-year acute phase with daily cycles and a lifetime long-term phase with annual cycles, was adapted to the Spanish setting. The model included a cohort of patients with severe VOD/SOS (defined as VOD/SOS with MOD) post-HCT. For the acute phase, efficacy and VOD/SOS-related length of stay were obtained from a phase 3 defibrotide study (NCT00358501). VOD/SOS-related hospital stays were 7.5 and 23.2 days in defibrotide-treated and BSC patients, respectively. Defibrotide-treated patients spent 30% of their stay in the intensive care unit vs 60% in BSC patients. Assumptions for the long-term phase and utility values were obtained from the literature. Costs were from the Spanish Health System perspective (€2019). Defibrotide cost was based on 25 mg/kg/day over 17.5 days, using local expert opinion. Life-years (LYs), quality-adjusted LYs (QALYs), and costs were estimated over a lifetime horizon, applying a 3% discount rate for costs and outcomes. Sensitivity analyses assessed the robustness of the results.Defibrotide produced an additional 1.214 QALYs and 1.348 LYs vs BSC, with a total cost of €33,708 more than BSC alone. However, defibrotide resulted in savings up to €16,644/patient for cost of hospital stay. Difference between costs and effective measures led to ratios of €27,757/QALY and €25,007/LY gained. Additional hospital stays had the greatest influence on base-case results. Probabilistic analysis confirmed the robustness of the deterministic results.Limitations include use of historical controls and assumptions extrapolated from the literature.This cost-effectiveness model, adapted to the Spanish setting, showed that defibrotide is a cost-effective alternative to BSC alone in patients with severe VOD/SOS post-HCT." @default.
• W3155313299 created "2021-04-26" @default.
• W3155313299 creator A5002868258 @default.
• W3155313299 creator A5006761861 @default.
• W3155313299 creator A5011478294 @default.
• W3155313299 creator A5042900099 @default.
• W3155313299 creator A5046857573 @default.
• W3155313299 creator A5053596447 @default.
• W3155313299 creator A5056283966 @default.
• W3155313299 creator A5062867509 @default.
• W3155313299 creator A5068265567 @default.
• W3155313299 date "2021-01-01" @default.
• W3155313299 modified "2023-10-08" @default.
• W3155313299 title "Cost-effectiveness analysis of defibrotide in the treatment of patients with severe veno-occlusive disease/sinusoidal obstructive syndrome with multiorgan dysfunction following hematopoietic cell transplantation in Spain" @default.
• W3155313299 cites W1779344217 @default.
• W3155313299 cites W1964887526 @default.
• W3155313299 cites W1973519172 @default.
• W3155313299 cites W1993783426 @default.
• W3155313299 cites W1996485480 @default.
• W3155313299 cites W2025029039 @default.
• W3155313299 cites W2045784916 @default.
• W3155313299 cites W2054671000 @default.
• W3155313299 cites W2061382057 @default.
• W3155313299 cites W2080375775 @default.
• W3155313299 cites W2097772781 @default.
• W3155313299 cites W2100770509 @default.
• W3155313299 cites W2122552116 @default.
• W3155313299 cites W2140741940 @default.
• W3155313299 cites W2151029305 @default.
• W3155313299 cites W2171602945 @default.
• W3155313299 cites W2295805773 @default.
• W3155313299 cites W2462936585 @default.
• W3155313299 cites W2501112626 @default.
• W3155313299 cites W2562591886 @default.
• W3155313299 cites W2565093155 @default.
• W3155313299 cites W2567289819 @default.
• W3155313299 cites W2619318678 @default.
• W3155313299 cites W2729928353 @default.
• W3155313299 cites W2793137791 @default.
• W3155313299 cites W2803440649 @default.
• W3155313299 cites W2905101562 @default.
• W3155313299 cites W2914402876 @default.
• W3155313299 cites W2917624759 @default.
• W3155313299 doi "https://doi.org/10.1080/13696998.2021.1916749" @default.
• W3155313299 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33858278" @default.
• W3155313299 hasPublicationYear "2021" @default.
• W3155313299 type Work @default.
• W3155313299 sameAs 3155313299 @default.
• W3155313299 citedByCount "3" @default.
• W3155313299 countsByYear W31553132992021 @default.
• W3155313299 countsByYear W31553132992022 @default.
• W3155313299 crossrefType "journal-article" @default.
• W3155313299 hasAuthorship W3155313299A5002868258 @default.
• W3155313299 hasAuthorship W3155313299A5006761861 @default.
• W3155313299 hasAuthorship W3155313299A5011478294 @default.
• W3155313299 hasAuthorship W3155313299A5042900099 @default.
• W3155313299 hasAuthorship W3155313299A5046857573 @default.
• W3155313299 hasAuthorship W3155313299A5053596447 @default.
• W3155313299 hasAuthorship W3155313299A5056283966 @default.
• W3155313299 hasAuthorship W3155313299A5062867509 @default.
• W3155313299 hasAuthorship W3155313299A5068265567 @default.
• W3155313299 hasBestOaLocation W31553132991 @default.
• W3155313299 hasConcept C109159458 @default.
• W3155313299 hasConcept C112930515 @default.
• W3155313299 hasConcept C126322002 @default.
• W3155313299 hasConcept C141071460 @default.
• W3155313299 hasConcept C177713679 @default.
• W3155313299 hasConcept C2777408962 @default.
• W3155313299 hasConcept C2777712501 @default.
• W3155313299 hasConcept C2780895475 @default.
• W3155313299 hasConcept C28328180 @default.
• W3155313299 hasConcept C2911091166 @default.
• W3155313299 hasConcept C2993713153 @default.
• W3155313299 hasConcept C3019080777 @default.
• W3155313299 hasConcept C54355233 @default.
• W3155313299 hasConcept C64332521 @default.
• W3155313299 hasConcept C71924100 @default.
• W3155313299 hasConcept C72563966 @default.
• W3155313299 hasConcept C86803240 @default.
• W3155313299 hasConceptScore W3155313299C109159458 @default.
• W3155313299 hasConceptScore W3155313299C112930515 @default.
• W3155313299 hasConceptScore W3155313299C126322002 @default.
• W3155313299 hasConceptScore W3155313299C141071460 @default.
• W3155313299 hasConceptScore W3155313299C177713679 @default.
• W3155313299 hasConceptScore W3155313299C2777408962 @default.
• W3155313299 hasConceptScore W3155313299C2777712501 @default.
• W3155313299 hasConceptScore W3155313299C2780895475 @default.
• W3155313299 hasConceptScore W3155313299C28328180 @default.
• W3155313299 hasConceptScore W3155313299C2911091166 @default.
• W3155313299 hasConceptScore W3155313299C2993713153 @default.
• W3155313299 hasConceptScore W3155313299C3019080777 @default.
• W3155313299 hasConceptScore W3155313299C54355233 @default.
• W3155313299 hasConceptScore W3155313299C64332521 @default.
• W3155313299 hasConceptScore W3155313299C71924100 @default.
• W3155313299 hasConceptScore W3155313299C72563966 @default.
• W3155313299 hasConceptScore W3155313299C86803240 @default.
• W3155313299 hasIssue "1" @default.
• W3155313299 hasLocation W31553132991 @default.

• next